The startup is developing medicines designed to overstress cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.” ...

Leading oncology drug developers raise $67 million in funding to target cancer's vulnerability to oncogene overactivation.

Julian Edelman had the crowd laughing after joking about Bill Belichick for not landing an NFL job after Robert Kraft's ...

Gov. Ron DeSantis signed five bills Wednesday that strengthen penalties for crimes against children, increase oversight of ...

High-capacity magazines and cheap devices that turn semi-automatic firearms into machine guns have already raised the ...

Next-generation approach targets cancer's surprising vulnerability to oncogene overactivation Delphia is leveraging its activation lethality platform to develop highly differentiated, first-in-class ...

Algonquin leaders are demanding accountability and seeking answers after learning Canadian Nuclear Laboratories discharged ...

Primary hepatocellular carcinoma (HCC), the major type of liver cancer, is a leading cause of worldwide cancer-related death. End-stage liver cancer patients have limited treatment options due to the ...

Australia aims to double the size of its naval fleet with its largest shipbuilding investment since World War II, but ...

I n a world where military strength and technological advancement are crucial, the Su-75 “Checkmate,” Russia’s proposed ...

Strong preclinical data from our two lead synthetic lethality programs – PRMT5 and WRN – are encouraging as we make progress toward the identification of competitive clinical candidates," said ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's ...